Compare iShares Russell 2000 ETF (IWM) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Russell 2000 ETF vs Nuwellis Inc — how do they compare? iShares Russell 2000 ETF trades at $279.16 (market cap $78.56B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: iShares Russell 2000 ETF is far larger — about 35709.1× Nuwellis Inc's market cap, and iShares Russell 2000 ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Russell 2000 ETF for 83 Days and Nuwellis Inc for 26 Days on average.
| IWM | NUWE | |
|---|---|---|
Market Cap | $78.56B | $2.20M |
Volume | 24,585,463 | 121,544 |
52-Week High | $305.06 | $146.65 |
52-Week Low | $229.13 | $0.68 |
Typical Hold Time | 83 Days | 26 Days |
Sector | — | Health |
Enterprise Value | — | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IWM trades at $277.72, down 1.27% with bearish technical signals from moving averages and key indicators. The ETF faces headwinds from Federal Reserve rate hikes and underperformance relative to large-cap indices. Recent news highlights IWM's decade-long trailing of the S&P 500 while carrying higher risk, with institutional selling pressure emerging.
The outlook remains challenging as small-caps face tightening financial conditions and energy price pressures. Investment opportunity exists for long-term value investors seeking diversification from tech-heavy large-caps, though near-term risks include continued Fed hawkishness and weak small-cap breadth in the current market environment.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
